Kura Oncology (KURA +1.3%) is up on lower-than-average volume on the heels of its announcement of updated results from a Phase 2 clinical trial assessing tipifarnib in patients with head and neck squamous cell carcinomas (HNSCC) with HRAS mutations. The data are being presented today at the Multidisciplinary Head and Neck Cancers Symposium in Scottsdale, AZ.
Nine HRAS mutation-positive HNSCC patients have been enrolled to date. 83% (n=5/6) of evaluable patients have experienced partial responses. The other one experienced tumor shrinkage and prolonged cancer stabilization. Two have shown durable responses of more than 18 months.
Recruitment is ongoing. Target enrollment is 36.
Tipifarnib inhibits an enzyme called farnesyl transferase. Interfering with its function inhibits protein farnesylation, a key signaling process in cancer initiation and development. Farnesyl transferase inhibitors have shown particular promise in blocking HRAS (an oncogene) farnesylation.
Subscribe for full text news in your inbox